SYD-3521 is under clinical development by Byondis and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SYD-3521’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SYD-3521 overview
SYD-3521 is under development for the treatment of solid tumor, ovarian cancer, cervical cancer, endometrial cancer, uveal melanoma, clear cell renal cell carcinoma (ccRCC), colorectal cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer. The therapeutic candidate is a antibody drug conjugate, comprised of the humanized IgG1 c-MET-targeting monoclonal antibody, SYD2884, and a cleavable linker-drug called valine-citrulline-seco-DUocarmycin-hydroxy Benzamide-Azaindole (vc-seco-DUBA or SYD980). It acts by targeting cancer cells expressing hepatocyte growth factor receptor expressed on tumor cell surface (c-Met). It is developed based on antibody drug conjugate (ADC) platform, proprietary duocarmazine linker-drug (LD) technology ByonZine and its site-specific conjugation technology ByonShieLD. It is a new molecular entity.
It was also under development for head and neck squamous cell carcinoma, papillary renal cell carcinoma (PRCC).
Byondis overview
Byondis, discovers and develops innovative precision medicines for the treatment of auto-immune diseases including cancer. The company’s pipeline includes trastuzumab, SYD985, BYON3521, BYON4228 and BYON4413. Its pipeline candidates treat breast and gastric cancer and endometrial cancer. It is advancing its lead candidate: SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate (ADC), and a portfolio of preclinical and clinical programs with an aim to provide novel treatments for solid tumors that overexpress HER2, uterine serous carcinoma and auto-immune diseases. It harnesses its proprietary linker-drug (LD) technology to generate ADCs targeting treatment for different indications. The company works in collaboration with pharmaceutical companies including Amgen, Allergan and Macrogenics; academic institutions; and medical communities worldwide. Byondis is headquartered in Nijmegen, Gelderland, the Netherlands.
For a complete picture of SYD-3521’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
